Lothspeich Emily, Werremeyer Amy, Chase Sarah, Huseth-Zosel Andrea
School of Pharmacy, North Dakota State University, Fargo, ND, USA.
Department of Pharmacy Practice, North Dakota State University, Fargo, ND, USA.
J Pharm Pract. 2023 Oct;36(5):1217-1224. doi: 10.1177/08971900221109528. Epub 2022 Jun 15.
Screening for patient-level opioid-related risk in the community pharmacy setting has increased patient education about opioids and naloxone distribution, helping to mitigate the impact of the opioid epidemic. However, patient experience and satisfaction with opioid screening and education is unknown. Fear of patient dissatisfaction may limit pharmacists' willingness to implement screening activities. To report patient experience and satisfaction of a convenience sample of patients undergoing screening and intervention for opioid-related risk as a part of the ONE Program (formerly ONE Rx). Patients who received ONE Program screening and intervention from their community pharmacist were recruited to participate in a 9 item survey regarding their experience and satisfaction. Results were analyzed by urban and rural location of participants. Urban (n = 42) and rural (n = 32) patients who completed the survey reported positive experiences namely feeling comfortable with the ONE process (86.5%), the process taking an appropriate amount of time (93.2%) and feeling safer as a result of their pharmacist's attention to their opioid-related medication risk (86.3%). Urban patients were significantly more likely than rural patients to report positive attitude and behavior changes as a result of the ONE process. High levels of patient satisfaction and positive experience with the ONE Program screening and intervention process for patient-level opioid-related risks may encourage community pharmacists to more broadly implement such activities.
在社区药房环境中筛查患者层面与阿片类药物相关的风险，增加了患者对阿片类药物和纳洛酮分发的了解，有助于减轻阿片类药物流行的影响。然而，患者对阿片类药物筛查和教育的体验及满意度尚不清楚。担心患者不满意可能会限制药剂师开展筛查活动的意愿。作为ONE项目（前身为ONE Rx）的一部分，报告接受阿片类药物相关风险筛查和干预的便利样本患者的体验和满意度。招募从社区药剂师处接受ONE项目筛查和干预的患者参与一项关于其体验和满意度的9项调查。结果按参与者的城乡地点进行分析。完成调查的城市患者（n = 42）和农村患者（n = 32）报告了积极的体验，即对ONE流程感到舒适（86.5%）、该流程耗时适当（93.2%）以及由于药剂师关注其与阿片类药物相关的用药风险而感觉更安全（86.3%）。城市患者比农村患者更有可能报告因ONE流程而出现积极的态度和行为改变。患者对ONE项目针对患者层面阿片类药物相关风险的筛查和干预流程的高度满意度和积极体验，可能会鼓励社区药剂师更广泛地开展此类活动。
